COVID-19 among fit patients with CLL treated with venetoclax-based combinations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Leukemia ; 34 (2020), 8. - S. 2225-2229. - ISSN 0887-6924. - eISSN 1476-5551
- Schlagwort
-
Infektionskrankheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Ulm
- (wer)
-
Universität Ulm
- (wann)
-
2020
- Urheber
-
Fürstenau, Moritz
Langerbeins, Petra
De Silva, Nisha
Fink, Anna Maria
Robrecht, Sandra
Tresckow, Julia von
Simon, Florian
Hohloch, Karin
Droogendijk, Jolanda
van der Klift, Marjolein
van der Spek, Ellen
Illmer, Thomas
Schöttker, Björn
Fischer, Kirsten
Wendtner, Clemens M.
Tausch, Eugen
Stilgenbauer, Stephan
Niemann, Carsten U.
Gregor, Michael
Kater, Arnon P.
Hallek, Michael
Eichhorst, Barbara
- DOI
-
10.18725/OPARU-51223
- URN
-
urn:nbn:de:bsz:289-oparu-51299-1
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fürstenau, Moritz
- Langerbeins, Petra
- De Silva, Nisha
- Fink, Anna Maria
- Robrecht, Sandra
- Tresckow, Julia von
- Simon, Florian
- Hohloch, Karin
- Droogendijk, Jolanda
- van der Klift, Marjolein
- van der Spek, Ellen
- Illmer, Thomas
- Schöttker, Björn
- Fischer, Kirsten
- Wendtner, Clemens M.
- Tausch, Eugen
- Stilgenbauer, Stephan
- Niemann, Carsten U.
- Gregor, Michael
- Kater, Arnon P.
- Hallek, Michael
- Eichhorst, Barbara
- Universität Ulm
Entstanden
- 2020
Ähnliche Objekte (12)
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Venetoclax bei der chronischen lymphatischen Leukämie (CLL)
BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Nowcasting Canadian GDP with density combinations
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Three allele combinations associated with Multiple Sclerosis
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Venetoclax bei der chronischen lymphatischen Leukämie (CLL)
BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Nowcasting Canadian GDP with density combinations
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Three allele combinations associated with Multiple Sclerosis
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Venetoclax bei der chronischen lymphatischen Leukämie (CLL)
BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Nowcasting Canadian GDP with density combinations
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Three allele combinations associated with Multiple Sclerosis
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia